Company
Software for the people who live with autoimmune disease, the clinicians who treat it and the researchers who study it. Built in Madrid.
Autoimmune disease reaches patients, clinicians and researchers. Neural Omega builds for all three, on one scientific foundation.
Each vertical has its own audience and its own products. The science and the principles beneath them are shared.
A private ecosystem where people living with autoimmune disease and the clinicians who treat them own a clinical picture that moves with them.
Infrastructure for new studies, discovery through molecular mimicry and our own research lines in advanced therapies.
Neural Omega was born from original research and grows milestone by milestone, each built on the last.
“If this is my alpha and omega, that everything heavy should become light, every body a dancer and every spirit a bird: truly, this is my alpha and omega.”
Our name was born from reading this passage of Thus Spoke Zarathustra, in which Zarathustra closes the same song seven times with the ring of rings, the one that joins the beginning to the end. Alpha is the first letter of the Greek alphabet and omega the last. Together they sum up an idea we made our own: embracing something whole, from beginning to end.
That idea fits the disease we have chosen. Autoimmunity is multifactorial, evolves over time and runs across specialties, consultations and years of diagnosis. Those who live with it, treat it and research it all carry that complexity. Our work is to take it whole and return it simple to those who need it.
To do so we rely on technology, and that is the other half of the name. Neural names the how: powerful, sophisticated systems, built with patience, that range from proteome-scale computation to the tools for patients and clinicians.
In science, that means studying molecular mimicry at proteome scale and presenting every result at its true level of validation. In product, it means tools designed so that a patient understands them from the first day and a clinician can bring them into practice. In research, it means infrastructure that any group can join.
This is how we grow: with a long horizon, from Madrid, with ethics built into every decision. Building with purpose means exactly that, knowing why each thing is done before doing it, from beginning to end.
“We work for people: for those who live with autoimmune disease, for those who treat it and for those who research it. Our work is to make the complex simple, with rigour, so that health and research move forward.”
Self-funded, the research behind the company begins: a proteome-scale molecular mimicry screen.
The screening methodology, developed independently, is presented and publicly defended as a final-year thesis in Medicine.
Neural Omega S.L. is incorporated in Madrid.
Neural Omega joins AseBio, the Spanish Bioindustry Association.
ENISA certifies Neural Omega as an emerging company.
ENISA backs the company with public funding and Phase I is completed.
Neural Omega presents its full pipeline to the international biotech community in Spain is Biotech, AseBio's international newsletter.
The company's ethics office is founded, led by our Chief Purpose Officer.
The Spanish Patent and Trademark Office grants the NEURAL OMEGA® trademark.
First public appearance, with our own stand and a presentation in the Startup Pitch Presentations: Drug Development & Delivery programme.
Neural Omega Health completes its first version and enters closed beta with professionals and patients.
We keep working with constancy and discretion, as always, on the next step of our mission: decoding autoimmunity.
A small team, working together entirely from Madrid.
Medical graduate and researcher in immunology and molecular mimicry, whose own research is the origin of the company. Architect of the technical platform, now leading strategy, execution and direction across both verticals.
LinkedInLeads Neural Omega's ethics, bioethics and corporate responsibility framework, from principles to practice. Keeps the science accountable to patients, professionals and industry partners as the company grows across both verticals.
LinkedInJoining our molecular mimicry line in autoimmunity. We'll introduce her on 16 November.
The facts behind Neural Omega, and where its science and its ethics are set out in full.
The line of inquiry behind every product, with the evidence and the references that support it.
The four principles of medical ethics, applied to data, AI and research.
Neural Omega grows in phases. The first, combining private and public capital, is complete.
Talk to us as an investor →Neural Omega has received financing from ENISA, Ministry of Industry and Tourism, funded by the European Union – NextGenerationEU under the Recovery, Transformation and Resilience Plan.
Clinicians, researchers, patient organisations, partners and investors are welcome to start a conversation.